CA-PULSESG
20.10.2021 15:02:13 CEST | Business Wire | Press release
pulsESG™ today announced the launch of its enterprise environmental, social, and governance (ESG) software as a service (SaaS) platform backed by $8.5 million in seed funding from leading impact-driven investors and led by two Silicon Valley enterprise software veterans. The platform distinguishes itself in the marketplace through features such as model-driven architecture and full integration with both internal sources of data and external investor-facing systems, empowering companies to track and derive insights for ESG compliance and improvement based on stakeholder requirements. The company emerged from stealth mode today and the product is expected to be made generally available in Q1 2022.
Led by tech veterans and co-founders Murat Sönmez and Inderjeet Singh, the pulsESG™ platform is designed to take a different approach to ESG analysis than what currently exists in the marketplace by providing comprehensive, auditable, and accurate deep analytics that can be integrated with both the source and destination ESG systems of customers. This new level of information empowers enterprises to make more informed ESG decisions using a platform that also provides end-users the flexibility to modify it based on changes in the ESG regulatory landscape and according to their stakeholder needs.
“Amidst changing impact benchmarks at national and global levels, accurate and reliable ESG analysis is moving from ‘nice-to-have’ to ‘must-have’ for enterprises worldwide, so we sought to develop a platform to help customers navigate this fluid landscape,” explained Co-founder, President, and CTO Inderjeet Singh. “The pulsESG™ platform was designed to raise the bar on quality and timeliness, allowing customers to respond to changes in the ESG models themselves, not just data points within current data models.”
“Simply put, pulsESG™ offers an integrated, comprehensive, and flexible SaaS platform for enterprises to define, capture, analyze, derive insight, and improve their ESG footprint,” added Murat Sönmez, Co-founder and CEO.
While private equity firms, their investors, and other stakeholders increasingly take ESG impacts and risk into account, the measurement tools and benchmarks for each continue to evolve—both across sectors and jurisdictions. Sönmez and Singh saw the opportunity to leverage their experience with SaaS platforms, integration, business processes, analytics, and master data management to create a system to help enterprises navigate and respond to this inherent fluidity in ESG analysis. The result of their vision is the pulsESG™ platform.
Sönmez and Singh have found early backing from leading investors in the impact-driven investment space, including FINTOP Capital, Aligned Climate Capital, SOMPO Holdings (Japan), Builders VC, eLab Ventures, and individual investors including Alberto Cribiore and André Borschberg.
Prior to co-founding pulsESG™, Murat Sönmez was a member of the founding team at TIBCO Software and led it past the billion-dollar revenue mark as the head of its customer facing operations. Sönmez later joined the Managing Board of the World Economic Forum in Switzerland, leading its global business community engagement efforts, and subsequently established and led its global technology policy network out of San Francisco.
pulsESG™ Co-founder Inderjeet Singh was most recently responsible for Oracle’s middleware and cloud platform and previously for TIBCO’s infrastructure products. Inderjeet joined TIBCO Software through the acquisition of Velosel—a leading master data management platform—where he was part of the founding team and led all product functions.
Investor Statements
“ESG reporting is quickly becoming standard practice for companies and investors worldwide. As an investor that cares deeply about ESG, we are excited about pulsESG’s ability to ensure that analysis and reporting is more real, reliable, and reportable."
— Peter W. Davidson, CEO, Aligned Climate Capital
"As one of the world’s largest economies, Japan faces pressure from an aging society with social impact and other ESG considerations steering business decisions more than ever. SOMPO has been working to address these issues in innovative ways and utilizing digital technologies to accurately measure our impact, so are excited to have found a partner in pulsESG—an integrated and comprehensive platform with the potential to accelerate SOMPO’s impact for society.”
— Kengo Sakurada, Group CEO, Director, President and Representative Executive Officer, SOMPO Holdings, Inc.
“In a crowded field of ESG platforms, Murat and Inderjeet stand apart with the completeness of their vision, passion for impact, and unparalleled combined experience in successfully scaling startups, developing mission-driven software platforms, and executing strategic engagement with top level leadership in organizations worldwide. We are pleased to lead the investment and look forward to an impactful journey together.”
— Rick Kushel, Co-founder and General Partner of FINTOP Capital
About pulsESG™
Founded in 2021, pulsESG, Inc. is a public benefit corporation dedicated to empowering purpose-driven enterprises to manage and improve their ESG footprint with an integrated and comprehensive SaaS platform built for compliance tracking and insight.
For more information: www.pulsESG.com
LinkedIn: www.linkedin.com/company/pulsESG
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom